BidaskClub upgraded shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) from a sell rating to a hold rating in a research report released on Wednesday morning.

Other equities analysts also recently issued reports about the company. ValuEngine upgraded Akebia Therapeutics from a sell rating to a hold rating in a research report on Friday, June 2nd. UBS AG restated a buy rating and set a $17.00 price objective (up from $12.00) on shares of Akebia Therapeutics in a research report on Friday, May 5th. HC Wainwright raised their price objective on Akebia Therapeutics from $18.00 to $21.00 and gave the stock a buy rating in a research report on Thursday, April 27th. Aegis restated a buy rating on shares of Akebia Therapeutics in a research report on Friday, June 30th. Finally, Needham & Company LLC restated a buy rating and set a $18.00 price objective (up from $14.00) on shares of Akebia Therapeutics in a research report on Thursday, April 27th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Akebia Therapeutics has an average rating of Buy and a consensus price target of $20.29.

Shares of Akebia Therapeutics (AKBA) traded down 0.20% during mid-day trading on Wednesday, reaching $14.99. The company’s stock had a trading volume of 263,008 shares. The company has a 50-day moving average of $13.95 and a 200-day moving average of $12.06. Akebia Therapeutics has a 12 month low of $7.16 and a 12 month high of $16.54. The firm’s market cap is $274.32 million.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.89) by $0.36. The firm had revenue of $28.52 million for the quarter, compared to analyst estimates of $26.50 million. On average, analysts predict that Akebia Therapeutics will post ($2.82) earnings per share for the current year.

WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/20/bidaskclub-upgrades-akebia-therapeutics-inc-akba-to-hold.html.

In other Akebia Therapeutics news, SVP Michel Dahan sold 5,000 shares of Akebia Therapeutics stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $15.00, for a total value of $75,000.00. Following the completion of the sale, the senior vice president now directly owns 102,224 shares in the company, valued at $1,533,360. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Muneer A. Satter bought 1,034,482 shares of the stock in a transaction on Wednesday, July 5th. The stock was acquired at an average price of $14.50 per share, with a total value of $14,999,989.00. The disclosure for this purchase can be found here. Insiders have sold 7,544 shares of company stock valued at $111,287 over the last 90 days. 7.95% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of AKBA. Arrowstreet Capital Limited Partnership increased its stake in shares of Akebia Therapeutics by 165.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 38,900 shares of the biopharmaceutical company’s stock worth $559,000 after buying an additional 24,222 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Akebia Therapeutics during the second quarter worth $159,000. RA Capital Management LLC acquired a new stake in shares of Akebia Therapeutics during the second quarter worth $12,018,000. State Street Corp increased its stake in shares of Akebia Therapeutics by 72.9% in the second quarter. State Street Corp now owns 946,888 shares of the biopharmaceutical company’s stock worth $13,604,000 after buying an additional 399,160 shares during the last quarter. Finally, DAFNA Capital Management LLC increased its stake in shares of Akebia Therapeutics by 92.7% in the second quarter. DAFNA Capital Management LLC now owns 135,738 shares of the biopharmaceutical company’s stock worth $1,951,000 after buying an additional 65,283 shares during the last quarter. Institutional investors and hedge funds own 46.34% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Analyst Recommendations for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.